NCT00600236

Brief Summary

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2004

Longer than P75 for phase_3 diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2004

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

June 30, 2006

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2008

Completed
23 days until next milestone

First Posted

Study publicly available on registry

January 24, 2008

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

Enrollment Period

3.3 years

First QC Date

June 30, 2006

Last Update Submit

May 31, 2024

Conditions

Diabetes Mellitus Type 2Proliferative Diabetic Retinopathy

Keywords

Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathyDiabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy

Interventions

blood samplePROCEDURE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
  • Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

You may not qualify if:

  • Systemic hipertension
  • Cardic disease
  • Lupus
  • Any kind of artritis
  • Allergies
  • Optic Neuritis
  • VKH
  • Cancer
  • Inmunological diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asociación para Evitar la Ceguera en México, Hospital "Luis Sanchez Bulnes"

Mexico City, Mexico DF, 04030, Mexico

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Hugo Quiroz-Mercado, MD

    Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes"

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
SINGLE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2006

First Posted

January 24, 2008

Study Start

September 1, 2004

Primary Completion

January 1, 2008

Study Completion

January 1, 2008

Last Updated

June 3, 2024

Record last verified: 2024-05

Locations

ME(1)